Form 10-Q AQUINOX PHARMACEUTICALS, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Leerink Maintains Aquinox Pharma (AQXP) at 'Outperform'; End-of-Phase 2 FDA Meeting is Next Catalyst
November 10, 2015 2:18 PM ESTLeerink affirms Aquinox Pharma (Nasdaq: AQXP) with an Outperform rating and $26 price target following the company's Q3 results and update... More
Aquinox Pharma (AQXP) Posts Narrower-than-Expected Q3 Loss
November 10, 2015 9:20 AM ESTAquinox Pharma (NASDAQ: AQXP) reported Q3 EPS of ($0.43), $0.02 better than the analyst estimate of ($0.45).
With positive results from the LEADERSHIP trial, we are advancing towards pivotal trials in bladder pain syndrome/interstitial cystitis (BPS/IC) with AQX-1125, said Mr. David Main, President and... More
